论文部分内容阅读
为探讨血清β-葡萄糖醛酸酶(β-G)活性测定在肝癌诊断中的价值,建立 ELISA 法测定不同肝脏疾病病人血清β-G 活性,并与甲胎蛋白(AFP)和γ-谷氨酰转肽酶(GGT)进行比较。31例肝癌病人血清β-G 活性(1:16.6±1.7)明显高于正常人(1:6.5±1.2)、肝硬化(1:7.4±1.6)及肝血管瘤(1:6.9±2.1),差异有非常显著性(P<0.01)。AFP、GGT 和β-G 三者,在肝癌诊断试验中灵敏度分别为67.7%、90.3%和80.6%;特异性为88.2%、76.5%和82.4%;准确度为75.0%、85.4%和81.3%,β-G 均位于 AFP 和 GGT 之间。结论:β-G 作为一种体内酶标志,对肝癌诊断有较大参考价值。
To investigate the value of serum β-glucuronidase (β-G) activity assay in the diagnosis of hepatocellular carcinoma, an ELISA method was established to measure serum β-G activity in patients with different liver diseases and to compare alpha-fetoprotein (AFP) and gamma-glutamine Acyl transferase (GGT) was compared. The serum β-G activity (1:16.6±1.7) was significantly higher in 31 HCC patients than in normal controls (1:6.5±1.2), cirrhosis (1:7.4±1.6), and hepatic hemangioma (1:6.9±2.1). The difference was very significant (P < 0.01). The sensitivity of AFP, GGT and β-G in the diagnosis of liver cancer was 67.7%, 90.3% and 80.6% respectively; the specificity was 88.2%, 76.5% and 82.4%; the accuracy was 75.0%, 85.4% and 81.3% β-G is located between AFP and GGT. Conclusion: β-G as an in vivo enzyme marker is of great value in the diagnosis of liver cancer.